Search - tctmd.com

Displaying 381 - 400 of 447

Sort: Relevancy | Date

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

Michael O'Riordan

January 17, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Michael O'Riordan

December 20, 2015

News Daily News

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Shelley Wood

December 16, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Michael O'Riordan

December 02, 2015

News Daily News

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Michael O'Riordan

December 02, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

News Daily News

研究表明他汀类药物治疗会降低流感疫苗的有效性

Yael L. Maxwell

November 03, 2015

Advertisement

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

TCTMD’s Top 10 Most Popular Stories for January 2016

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

研究表明他汀类药物治疗会降低流感疫苗的有效性

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content